Medtronic in hot seat over Fidelis recall
This article was originally published in The Silver Sheet
Medtronic's decision last month to halt worldwide distribution of its Sprint Fidelis defibrillator leads has attracted congressional scrutiny of the company's response to data showing the leads were vulnerable to fracture. The attention, reminiscent of that surrounding Guidant's ICD recalls in 2005, stems from Medtronic's Oct. 15 announcement advising physicians to stop implanting four models of Fidelis leads and return unused product to the company. FDA, which classified the recall as Class I, began closely monitoring Fidelis in February when cardiologist Robert Hauser, M.D., of the Minneapolis Heart Institute contacted FDA about problems with the lead's performance. "What I find troubling is that Medtronic took months to stop the sales of the faulty lead, even though the problem had been reported in a peer-reviewed journal months prior," Sen. Chuck Grassley, R-Iowa, wrote to Medtronic CEO Bill Hawkins Oct. 16. Grassley and House Committee on Oversight and Government Reform Chair Henry Waxman, D-Calif., have also sent letters to FDA requesting information on the agency's oversight of Medtronic's Fidelis leads
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.